InMed Pharmaceuticals is pleased to welcome the BayMedica team following its acquisition in October 2021. Meet Dr. Charles Marlowe, our VP of Chemistry.
Chuck talks about how he got started in the biosynthesis and chemical synthesis of cannabinoids. He and other BayMedica co-founders, Philip Barr and Shane Johnson, came together to apply their expertise in chemistry, yeast biosynthesis and drug discovery to develop synthesized cannabinoids. The team has been able to produce biosynthetic versions of the naturally occurring cannabinoids as well as new cannabinoid analogues – with Chuck contributing his chemistry expertise.
Chuck is excited to work with InMed and talks about the complementary technologies and skillset and how the two teams have hit the ground running.
Chuck has held roles at COR Therapeutics, Millennium Pharmaceuticals, Chiron Corporation, Takeda and Exelixis Inc. and has beeninstrumental in helping drive a number of small molecule therapeutics to entry into later-stage clinical trials and FDA approval. Chuck has authored over 30 publications in leading journals and holds over 25 issued world and U.S. patents. He holds a Ph.D. in organic chemistry from UC Berkeley, and was an NIH Postdoctoral fellow at Stanford University.
